- Conditions
- Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Interventions
- Magnetic Resonance Imaging using 7 Tesla MRI
- Diagnostic Test
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 553–576
of 1,873
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Thyroid Cancer, Breast Cancer, Non-Melanoma Skin Cancer, Melanoma
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 6,093 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2001 – 2020
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Metastatic Uveal Melanoma
- Interventions
- ZIV-Aflibercept, Cemiplimab
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Tampa, Florida • Chicago, Illinois + 1 more
- Conditions
- Macular Edema, Cystoid Macular Edema, Uveal Melanoma, Radiation Maculopathy, Radiation Retinopathy
- Interventions
- Ozurdex, Bevacizumab
- Drug
- Lead sponsor
- Arman Mashayekhi
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Melanoma (Skin)
- Interventions
- Not listed
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Colorectal Cancer, Endometrial Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Melanoma (Skin), Pancreatic Cancer, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- aldesleukin, ras peptide cancer vaccine, sargramostim, DetoxPC
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Melanoma
- Interventions
- Ipilimumab, Axitinib
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Metastatic Melanoma
- Interventions
- E7080
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 2
- States / cities
- Dallas, Texas • Houston, Texas
- Conditions
- DMG, DIPG
- Interventions
- TAA-T Cell, BBB Disruption
- Biological · Device
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 3 Years to 25 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Metastatic Cancer
- Interventions
- Genetically Informed Therapy
- Genetic
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Ovarian Carcinoma, Metastatic Renal Cell Carcinoma, Platinum-Resistant Ovarian Carcinoma, Recurrent Melanoma, Recurrent Renal Cell Carcinoma, Refractory Melanoma, Refractory Renal Cell Carcinoma, Sarcoma, Stage IV Colorectal Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Elastography, Pembrolizumab, Ziv-Aflibercept
- Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 7
- States / cities
- Tampa, Florida • Bethesda, Maryland • Boston, Massachusetts
- Conditions
- Metastatic Melanoma
- Interventions
- Vaccination
- Biological
- Lead sponsor
- John Kirkwood
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2014
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Advanced Cancer, Metastatic Melanoma, Metastatic Non-small Cell Lung Cancer, Colorectal Cancer
- Interventions
- LY3214996, Midazolam, Abemaciclib, Nab-paclitaxel, Gemcitabine, Encorafenib, Cetuximab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 8
- States / cities
- Washington D.C., District of Columbia • Sarasota, Florida • Boston, Massachusetts + 4 more
- Conditions
- Metastatic Melanoma, Nausea
- Interventions
- Not listed
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Melanoma; Renal Cell Carcinoma
- Interventions
- Blood collection for laboratory studies, Data collection from medical record
- Other
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2027
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Melanoma
- Interventions
- Fianlimab, Cemiplimab, Pembrolizumab, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,564 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 28
- States / cities
- La Jolla, California • San Francisco, California • Santa Monica, California + 21 more
- Conditions
- Solid Tumor, Lymphoma
- Interventions
- Arm A: RPTR-147:1, Arm B: RPTR-147:1 and Pembrolizumab, Arm C: RPTR-147:2
- Biological
- Lead sponsor
- Repertoire Immune Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 7
- States / cities
- Duarte, California • New Haven, Connecticut • Boston, Massachusetts + 4 more
- Conditions
- Metastatic Melanoma, Advanced Melanoma, Metastatic Melanoma Stratified by MHC-II Expression
- Interventions
- Nivolumab, Relatlimab, Ipilimumab
- Drug
- Lead sponsor
- Elizabeth Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Melanoma, Metastatic Kidney Cancer
- Interventions
- Interleukin-2 (IL-2)
- Drug
- Lead sponsor
- Loma Linda University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- Beaumont, California • Loma Linda, California
- Conditions
- Melanoma Stage III, Melanoma Stage IV
- Interventions
- Nivolumab, BMS-986205, Ipilimumab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
- Interventions
- Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Melanoma (Skin)
- Interventions
- recombinant vaccinia-TRICOM vaccine
- Biological
- Lead sponsor
- Herbert Irving Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation, MDM2 Gene Mutation, Cutaneous Melanoma, Mucosal Melanoma, Malignant Peripheral Nerve Sheath Tumors (MPNST)
- Interventions
- Phase 1b: APG-115+pembrolizumab
- Drug
- Lead sponsor
- Ascentage Pharma Group Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 17
- States / cities
- Tucson, Arizona • Rogers, Arkansas • Los Angeles, California + 14 more
- Conditions
- Uveal Melanoma
- Interventions
- Darovasertib, Primary Local Therapy
- Drug · Procedure
- Lead sponsor
- IDEAYA Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 35
- States / cities
- Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 26 more